↓ Skip to main content

Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors

Overview of attention for article published in Frontiers in Pharmacology, February 2021
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
3 Mendeley